Learn more about our Diagnostics work.
BOSTON and NEW YORK, April 14, 2025 /PRNewswire/ — Satio and Nanowear have agreed to partner to advance patient-friendly, home-based diagnostic, and therapeutic care. This collaboration integrates Nanowear’s at-home AI-based nanotechnology biomarker diagnostic platform with Satio’s at-home…
WASHINGTON – AdvaMed, the Medtech Association, today commended Senators Mike Rounds (R-SD) and Martin Heinrich (D-NM) for introducing the Health Tech Investment Act (S. 1399). This landmark bipartisan legislation will…
AdvaMed®’s medtech priorities for the 119th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.
AdvaMed®’s medtech priorities for the 119th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.
One of healthcare’s most extensive and rapidly expanding market segments, Pointof-Care (POC) and at-home rapid diagnostic testing, has become an ever-increasing crucial topic in the medical world since COVID-19 was…
Today, Zach Rothstein, Executive Director of AdvaMedDx®, testified before the House Energy and Commerce Committee, Subcommittee on Health during a hearing on diagnostic test regulation and FDA’s proposed laboratory developed…
This February, AdvaMed® is working with member companies and our global partners to raise awareness and highlight the ways medical technology helps those living with cardiovascular disease live healthier, happier…
Today, AdvaMedDx® submitted comments in response to the Food and Drug Administration’s Proposed Rule: Medical Devices; Laboratory Developed Tests. AdvaMedDx® is a division of AdvaMed® representing companies that develop in…
Today, AdvaMedDx®, a division of AdvaMed® representing manufacturers of innovative in vitro diagnostic tests, sent a letter urging Congressional leaders to prioritize the reauthorization of the President’s Emergency Plan for…
AdvaMed®, the Medtech Association, released the following statement from President and CEO Scott Whitaker and Zach Rothstein, Executive Director of AdvaMedDx®, on FDA’s recently proposed LDT rule.